Zhejiang Starry PharmaceuticalLtd Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Zhejiang Starry PharmaceuticalLtd's earnings have been declining at an average annual rate of -35.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 14.3% per year. Zhejiang Starry PharmaceuticalLtd's return on equity is 0.5%, and it has net margins of 0.6%.
Belangrijke informatie
-35.1%
Groei van de winst
-35.6%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 10.9% |
Inkomstengroei | 14.3% |
Rendement op eigen vermogen | 0.5% |
Nettomarge | 0.6% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
There's No Escaping Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Muted Revenues
Sep 30Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality
May 06Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost
Mar 12Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?
Feb 28Opbrengsten en kosten
Hoe Zhejiang Starry PharmaceuticalLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 2,370 | 14 | 256 | 129 |
30 Jun 24 | 2,443 | 32 | 254 | 132 |
31 Mar 24 | 2,272 | 47 | 230 | 132 |
31 Dec 23 | 2,196 | 44 | 216 | 135 |
30 Sep 23 | 2,385 | -56 | 207 | 141 |
30 Jun 23 | 2,273 | -105 | 206 | 136 |
31 Mar 23 | 2,180 | -147 | 216 | 139 |
31 Dec 22 | 2,131 | -76 | 216 | 133 |
30 Sep 22 | 2,066 | 124 | 208 | 138 |
30 Jun 22 | 2,087 | 232 | 191 | 133 |
31 Mar 22 | 2,153 | 339 | 174 | 128 |
31 Dec 21 | 2,000 | 324 | 164 | 125 |
30 Sep 21 | 1,631 | 260 | 159 | 113 |
30 Jun 21 | 1,500 | 255 | 166 | 105 |
31 Mar 21 | 1,440 | 258 | 159 | 99 |
31 Dec 20 | 1,367 | 239 | 154 | 88 |
30 Sep 20 | 1,370 | 231 | 141 | 83 |
30 Jun 20 | 1,395 | 217 | 136 | 76 |
31 Mar 20 | 1,306 | 175 | 133 | 75 |
31 Dec 19 | 1,309 | 170 | 128 | 78 |
30 Sep 19 | 1,242 | 146 | 145 | 65 |
30 Jun 19 | 1,098 | 122 | 125 | 78 |
31 Mar 19 | 988 | 112 | 115 | 70 |
31 Dec 18 | 890 | 94 | 107 | 66 |
30 Sep 18 | 794 | 98 | 84 | 70 |
30 Jun 18 | 742 | 94 | 64 | 79 |
31 Mar 18 | 712 | 77 | 74 | 66 |
31 Dec 17 | 711 | 83 | 84 | 53 |
30 Sep 17 | 712 | 84 | 96 | 35 |
30 Jun 17 | 712 | 84 | 136 | 0 |
31 Mar 17 | 698 | 79 | 134 | 0 |
31 Dec 16 | 673 | 76 | 132 | 0 |
30 Sep 16 | 716 | 81 | 135 | 0 |
30 Jun 16 | 691 | 74 | 130 | 0 |
31 Mar 16 | 661 | 60 | 124 | 0 |
31 Dec 15 | 696 | 69 | 119 | 0 |
31 Dec 14 | 658 | 68 | 91 | 0 |
31 Dec 13 | 686 | 64 | 79 | 0 |
Kwaliteitswinsten: 603520 has a large one-off loss of CN¥27.4M impacting its last 12 months of financial results to 30th September, 2024.
Groeiende winstmarge: 603520 became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 603520's earnings have declined by 35.1% per year over the past 5 years.
Versnelling van de groei: 603520 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: 603520 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 603520's Return on Equity (0.5%) is considered low.